Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

SAN FRANCISCO, California. (June 25, 2018) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced the underwriters have exercised in full their option to purchase an additional 694,736 shares of KindredBio’s common stock at $9.50 per share, less underwriting discounts and commissions. KindredBio also […]

Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program

San Francisco, California. (June 20, 2018) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its “at-the-market” equity offering program (the “ATM Facility”) with B. Riley FBR, Inc. and Oppenheimer & Co. Inc. as sales agents. “With the recent successful […]

Kindred Biosciences Announces Pricing of Public Offering

SAN FRANCISCO, California. (June 20, 2018) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,631,578 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount […]

Kindred Biosciences Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, California. (June 19, 2018) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when […]

KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses

SAN FRANCISCO, May 30, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses. This study was a randomized, single-blind, placebo-controlled, dose-ranging study that enrolled 53 horses (40 […]